||Transforming growth factor beta type II (TGFbeta RII) is a key inhibitor of epithelial cell growth and tumor suppressor gene. It also regulate cell differentiation and has critical regulatory roles in the process of tissue repair and remodeling. TGF beta RII plays an important role as a tumor suppressor in non-small cell lung cancer (NSCLC) carcinogenesis. TGF can be found in many different tissue types, including brain, heart, kidney, liver and testes. Over-expression of TGF can induce renal fibrosis, causing kidney disease, as well as diabetes, and ultimately end-stage renal disease (ESRD). Recent developments have found that, using certain types of protein antagonists against TGFβ receptors, can halt and in some cases reverse the effects of renal fibrosis. Three TGF-β receptor types can be distinguished by their structural and functional properties. Receptor types I and II have similar ligand binding affinities and can only be distinguished from each other by peptide mapping, both receptor types I and II have a high affinity for TGF-β1 and low affinity for TGF-β2. TGF-β receptor type III has a high affinity for both TGF-β1 and -β2.
||The predicted molecular weight of Recombinant Human TGF-β sRII is Mr 82 kDa.
|State Of Matter:
||>97% by SDS Page and analyzed by silver stain.
||<1.0 EU/µg as determined by the LAL method.
||The biological activity of Human TGF-β sRII was determined by its ability to inhibit TGF-β1 activity on a mouse T cell line, HT2. The expected ED50 for this effect is typically 10 - 40 ng/mL in the presence of 1 ng/mL of rhTGF-β1.
|Storage And Stability:
||This lyophilized protein is stable for six to twelve months when stored desiccated at -20℃ to -70℃. After aseptic reconstitution, this protein may be stored at 2℃ to 8℃ for one month or at -20℃ to -70℃ in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.